We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-11.09%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.96B
AUM Growth
-$1.12B
Cap. Flow
-$87.3M
Cap. Flow %
-2.94%
Top 10 Hldgs %
72.49%
Holding
61
New
8
Increased
6
Reduced
4
Closed
10
Avg Time Held Equity + Options
6.6 quarters
Top 10 Avg Time Held Equity + Options
7.1 quarters
Top 20 Avg Time Held Equity + Options
7.6 quarters
Avg Time Held Equity only
6.8 quarters
Top 10 Avg Time Held Equity only
7.1 quarters
Top 20 Avg Time Held Equity only
7.6 quarters

Top Buys

Rank Stock Value
1
APLS icon
Apellis Pharmaceuticals
APLS
+$239M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$205M
3
MRSN icon
Mersana Therapeutics
MRSN
+$36.8M
4
ARVN icon
Arvinas
ARVN
+$35.6M
5
SLRN icon
ACELYRIN
SLRN
+$29.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$419M
2
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$124M
3
BPMC icon
Blueprint Medicines
BPMC
+$114M
4
RVMD icon
Revolution Medicines
RVMD
+$48.1M
5
DYN icon
Dyne Therapeutics
DYN
+$8.99M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Miscellaneous 1.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$423M
$559M 18.85%
11,584,280
– –
2018 Q4
19 quarters
APLS icon
2
DELISTED
Apellis Pharmaceuticals
APLS
$415M 13.99%
10,899,859
+5,448,212
+100% +$239M
2021 Q4
7 quarters
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$250M 8.45%
+5,748,399
New +$205M
2023 Q3
0 quarters
LKFT icon
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.87B
$199M 6.71%
5,756,268
– –
2021 Q3
8 quarters
RVMD icon
5
Revolution Medicines
RVMD
$40B
$154M 5.21%
5,577,863
-1,620,837
-23% -$48.1M
2022 Q1
6 quarters
ANAB icon
6
AnaptysBio
ANAB
$1.36B
$135M 4.56%
7,521,024
– –
2019 Q4
15 quarters
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$3.2B
$125M 4.21%
5,991,479
– –
2021 Q4
7 quarters
ARVN icon
8
Arvinas
ARVN
$445M
$107M 3.62%
5,467,063
+1,449,275
+36% +$35.6M
2021 Q4
7 quarters
XNCR icon
9
Xencor
XNCR
$1.74B
$106M 3.59%
5,282,516
– –
2018 Q4
19 quarters
TNGX icon
10
Tango Therapeutics
TNGX
$3.72B
$98.2M 3.31%
8,721,636
+4,674,522
+116% +$28.5M
2020 Q3
12 quarters
ZYME icon
11
Zymeworks
ZYME
$1.79B
$85.2M 2.87%
13,437,473
– –
2022 Q4
3 quarters
SWTX icon
12
DELISTED
SpringWorks Therapeutics
SWTX
$80M 2.7%
3,460,208
– –
2022 Q3
4 quarters
KURA icon
13
Kura Oncology
KURA
$862M
$53M 1.79%
5,806,871
– –
2015 Q4
31 quarters
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$13.6B
$47.7M 1.61%
368,411
– –
2023 Q2
1 quarter
CRNX icon
15
DELISTED
Crinetics Pharmaceuticals
CRNX
$45.5M 1.54%
1,530,263
+200,000
+15% +$4.12M
2021 Q4
7 quarters
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$36.4M 1.23%
5,618,779
– –
2021 Q2
9 quarters
RLAY icon
17
Relay Therapeutics
RLAY
$3.74B
$35M 1.18%
4,163,824
– –
2020 Q3
12 quarters
MORF icon
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$33.9M 1.14%
1,480,190
-2,366,774
-62% -$124M
2019 Q2
17 quarters
VYGR icon
19
Voyager Therapeutics
VYGR
$129M
$29.8M 1.01%
3,851,507
– –
2021 Q3
8 quarters
NMRA icon
20
Neumora Therapeutics
NMRA
$72.5M
$29.2M 0.99%
+2,071,450
New +$25.9M
2023 Q3
0 quarters
APLS icon
21
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$27.9M 0.94%
+732,500
New +$32.2M
2023 Q3
0 quarters
ALEC icon
22
Alector
ALEC
$205M
$26.3M 0.89%
4,056,548
– –
2021 Q1
10 quarters
NUVB icon
23
Nuvation Bio
NUVB
$1.64B
$25.7M 0.87%
19,209,643
+5,313,100
+38% +$8.84M
2021 Q1
10 quarters
MRSN icon
24
DELISTED
Mersana Therapeutics
MRSN
$24.6M 0.83%
+774,588
New +$36.8M
2023 Q3
0 quarters
OVID icon
25
Ovid Therapeutics
OVID
$410M
$23.5M 0.79%
6,117,400
– –
2021 Q1
10 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2023 Portfolio in Review

As of Q3 2023, EcoR1 Capital held 61 positions worth $2.96B, down 27% from $4.08B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital's Q3 2023 filing shows 8 new, 6 increased, 4 reduced and 10 closed positions. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 5,748,399 shares worth $250M. The largest sale was Sarepta Therapeutics, an estimated $419M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2023 buy was Mirati Therapeutics, Inc. Common Stock: 5,748,399 shares worth $250M.
  • EcoR1 Capital added most to Apellis Pharmaceuticals in Q3 2023, an estimated $239M increase.
  • EcoR1 Capital's biggest Q3 2023 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $124M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2023, selling an estimated $419M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.96B portfolio in Q3 2023.
  • EcoR1 Capital opened 8 new positions and closed 10 in Q3 2023.
  • EcoR1 Capital's portfolio value fell 27% quarter-over-quarter to $2.96B.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.